Anebulo Pharmaceuticals | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.05, beating the estimate of USD -0.12.

EBIT: As of FY2026 Q1, the actual value is USD -2.352 M.

Operating Expenses

Operating expenses for the first quarter of fiscal 2026 were $2.3 million, compared to $2.4 million in the same period of fiscal 2025.

Net Loss

Net loss for the first quarter of fiscal 2026 was $2.2 million, or - $0.05 per share, compared to a net loss of $2.2 million, or - $0.08 per share, in the first quarter of fiscal 2025.

Cash and Cash Equivalents

Cash and cash equivalents were $10.4 million as of September 30, 2025. The company also has access to an additional $3.0 million in cash through a Loan Agreement.

Total Assets and Liabilities

Total assets as of September 30, 2025, were $10.7 million, with total liabilities amounting to $963,821.

Outlook / Guidance

Anebulo Pharmaceuticals anticipates selonabant will rapidly reverse key symptoms of acute cannabis-induced toxicity. The company is prioritizing the advancement of a selonabant IV formulation for pediatric patients, which it believes offers a faster timeline to approval compared to the adult oral product.